AdvanCell Establishes U.S. Global HQ and Manufacturing Facility in Greater Boston  

Editor’s take: New facility and partnership with a leading CDMO expands AdvanCell’s U.S. clinical and commercial manufacturing infrastructure for ADVC001 and its Lead-212 targeted alpha therapy pipeline.

AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, established its U.S. Global Headquarters in the Greater Boston area, and leased a new 128,000-sq.-ft. facility that will serve as its U.S. flagship manufacturing center. The expansion integrates operations spanning North America and Australia.

The investment reflects AdvanCell’s strategy to expand its U.S. presence and build the infrastructure needed to support the development and future commercialization of ADVC001 and its Lead-212 targeted alpha therapy pipeline.

Located in Greater Boston, the Innovation Park campus owned by IQHQ provides access to a world-class life-science ecosystem. 

As part of its U.S. manufacturing expansion strategy, AdvanCell is also working with a leading CDMO to establish drug product manufacturing capabilities in addition to the Andover facility fit out and qualification. This approach aims to accelerate access to U.S.-based manufacturing capacity, supporting its Phase 2 TheraPb study (NCT05720130) in the U.S. while the company further builds its Phase 3 and commercial manufacturing infrastructure.

“Establishing AdvanCell’s U.S. Global Headquarters and future manufacturing facility reinforces our commitment to U.S. expansion and represents an important milestone in AdvanCell’s strategy to build a global, vertically integrated targeted alpha therapy company,” said Philina Lee, PhD, CEO of AdvanCell. “As we advance ADVC001 and our broader Lead-212 pipeline, our Andover facility will be a cornerstone of our U.S. expansion and our first internal manufacturing site in the U.S., providing the foundation to scale production to support future clinical and commercial demand. We will continue to leverage the strengths of our Australian operations – including rapid clinical translation, isotope supply capabilities and process innovation – as we advance our Lead-212 targeted alpha therapies for patients globally.”